MaxCyte, Inc. (NASDAQ:MXCT) Position Lifted by Blair William & Co. IL

Blair William & Co. IL raised its stake in MaxCyte, Inc. (NASDAQ:MXCT) by 3.6% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 282,859 shares of the company’s stock after purchasing an additional 9,900 shares during the period. Blair William & Co. IL owned 0.27% of MaxCyte worth $1,177,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of MXCT. Intech Investment Management LLC bought a new stake in MaxCyte in the third quarter valued at about $51,000. Prudential Financial Inc. bought a new stake in shares of MaxCyte in the 4th quarter valued at approximately $65,000. Catalyst Funds Management Pty Ltd acquired a new stake in shares of MaxCyte during the 4th quarter valued at approximately $74,000. Verition Fund Management LLC raised its position in shares of MaxCyte by 39.5% during the 3rd quarter. Verition Fund Management LLC now owns 21,335 shares of the company’s stock valued at $83,000 after acquiring an additional 6,045 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. boosted its holdings in MaxCyte by 10.7% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 22,366 shares of the company’s stock worth $93,000 after purchasing an additional 2,154 shares during the period. Institutional investors and hedge funds own 68.81% of the company’s stock.

Analyst Upgrades and Downgrades

MXCT has been the topic of a number of research reports. BTIG Research set a $6.00 target price on shares of MaxCyte and gave the stock a “buy” rating in a report on Wednesday, March 12th. Stifel Nicolaus dropped their price objective on shares of MaxCyte from $11.00 to $9.00 and set a “buy” rating on the stock in a research note on Wednesday, March 12th.

MaxCyte Price Performance

Shares of NASDAQ MXCT opened at $2.76 on Thursday. MaxCyte, Inc. has a 1-year low of $2.62 and a 1-year high of $5.26. The firm has a market capitalization of $292.64 million, a PE ratio of -8.12 and a beta of 1.35. The business’s fifty day moving average price is $3.72 and its two-hundred day moving average price is $3.87.

About MaxCyte

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.